MedTrace Logo

CAR T Cells in Mesothelin Expressing Cancers

NCT03054298 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-04-29

Study results available
· View outcomes & findings →

Summary

Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.

Conditions

Interventions

BIOLOGICAL

huCART-meso cells

Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Tmunity Therapeutics, a wholly owned subsidiary of Kite Pharma (a Gilead company)

    collaborator UNKNOWN

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Janos L Tanyi, MD, PhD · University of Pennaylvania

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-06
Primary Completion
2023-11-09
Completion
2024-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03054298 on ClinicalTrials.gov